Peripheral T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results first demonstrated that the activation of the IL2RG/JAK3/STAT5 signalling pathway contributed greatly to the oncogenic progress regulated by ITK‑SYK, supporting further investigation of JAK3 inhibitors for the treatment of PTCLs carrying the ITK‑SYK fusion gene.
|
31545408 |
2019 |
Peripheral T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical trials of targeted agents, as well as development of better preclinical models of PTCL, are leading to therapeutic advances in the field, including the development of phosphoinositide-3-kinase inhibitors, histone deacetylase inhibitor-based strategies, CD30-directed strategies, Janus kinase inhibitors, and spleen-associated tyrosine kinase inhibitors.
|
31808829 |
2019 |
Peripheral T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we characterized the role of ITK-FER [Interleukin-2-inducible T-cell Kinase (ITK) gene fused with Feline Encephalitis Virus-Related kinase (FER) gene] and ITK-SYK [Interleukin-2-inducible T-cell Kinase (ITK) gene fused with the Spleen Tyrosine Kinase (SYK)] in Peripheral T Cell Lymphoma (PTCL) signaling.
|
30217447 |
2018 |
Peripheral T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Around one fifth of PTCL-F exhibits t(5;9)(q33;q22)/ITK-SYK chromosomal translocation, which is essentially absent in AITL.
|
25337257 |
2014 |
Peripheral T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the t(5, 9)(q33;q22) translocation was found in a subset of peripheral T cell lymphomas and was shown to result in an IL-2-inducible kinase-spleen tyrosine kinase (ITK-Syk) fusion transcript.
|
24376268 |
2014 |
Peripheral T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent findings identified ITK-SYK as the first recurrent translocation in 17% of unspecified PTCLs and showed the overexpression of SYK in more than 90% of PTCLs.
|
20670954 |
2010 |
Peripheral T-Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A newly developed model of peripheral T cell lymphoma (PTCL) using the ITK-SYK fusion gene should serve as a powerful tool to dissect the signaling cascades important for SYK-associated malignancy in the context of t(5;9) PTCL.
|
20439538 |
2010 |
Peripheral T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ultimately, conditional expression of patient-derived ITK-SYK in mice induces highly malignant PTCLs with 100% penetrance that resemble the human disease.
|
20439541 |
2010 |
Peripheral T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Rare cases of peripheral T-cell lymphomas with follicular growth pattern (PTCL-F) have been recently reported, and their association with t(5;9)(q33;q22) involving ITK and SYK has been suggested.
|
19295409 |
2009 |
Peripheral T-Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The recent finding of SYK/ITK translocations in rare PTCLs led us to examine the expression of Syk PTK in 141 PTCLs.
|
18401419 |
2008 |
Peripheral T-Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ITK-SYK transcripts were detected in five of 30 (17%) unspecified PTCL, but not in cases of angioimmunoblastic T-cell lymphoma (n=9) and anaplastic lymphoma kinase-negative anaplastic large-cell lymphoma (n=7).
|
16341044 |
2006 |